RT Journal Article
SR Electronic
T1 Gut-derived PPAR-γ signaling and risk of bacterial enteric infection: insight from thiazolidinedione users in a US population-based study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.24.24313682
DO 10.1101/2024.09.24.24313682
A1 Birabaharan, Morgan
A1 Kaelber, David C
A1 Nizet, Victor
A1 Zarrinpar, Amir
YR 2024
UL http://medrxiv.org/content/early/2024/12/15/2024.09.24.24313682.abstract
AB Background and Aims The ongoing antimicrobial resistant crisis heralds the need for new therapeutics against enteric infection. In mouse models, colon epithelial peroxisome proliferator-activated receptor-γ (PPAR-γ) signaling limits oxygen and nitrate luminal bioavailability, thereby preventing bacterial pathogen colonization. However, whether this mechanism operates similarly in humans remains uncertain.Methods To investigate, we used the cloud-based TriNetX Analytics Platform which aggregates health records from 117 million patients across 66 US healthcare organizations, to assess the risk of bacterial enteric infection among diabetic patients prescribed thiazolidinediones, a class of PPAR-γ agonists, to other anti-diabetes medications.Results Among 85,117 thiazolidinedione users, we observed a 22-49% lower risk of bacterial enteric infections compared to users of other anti-diabetes medications. This reduction in risk was consistent across high-risk individuals, regardless of sex or age. Similar results were replicated in high-risk patients when thiazolidinedione users were directly compared to those on DPP-4 inhibitors.Conclusion These findings support the potential protective role of PPAR-γ signaling against bacterial enteric infection and call for further clinical investigation.Competing Interest StatementVN has served as a consultant and on the scientific advisory board for Cellics Therapuetics, I2Pure Inc, Clarametyx Therapeutics, and has licensed technology from lab sponsored research with Vaxcyte, Inc. AZ is a co-founder and acting CMO of Endure Biotherapeutics. He holds equity in the company.Funding StatementMB is supported by T32 AI007036. DCK is supported by the Clinical and Translational Science Collaborative of Northern Ohio which is funded by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health, UM1TR004528. AZ is supported by NIH R01 EB030134, R01 AI163483, U01 CA265719, and VA Merit BLR&D Award I01 BX005707. All authors receive institutional support from NIH P30 DK120515, P30 DK063491, and UL1 TR001442.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:live.trinetx.comI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes